The stratification of patients based on NR5A2 expression allows the distinction in two groups, with an association between low levels of NR5A2 and a higher prevalence of chronic pancreatitis and PDA development [82,84]. The gene discussed is NR5A2; the disease is Patent ductus arteriosus.